<DOC>
	<DOCNO>NCT01041248</DOCNO>
	<brief_summary>Relapsing polychondritis ( RP ) rare , immune-mediated disease associate inflammation cartilaginous structure tissue throughout body . Prognosis poor , especially case acute involvement laryngotracheal cartilage lead airway destruction , resistant treatment corticosteroid , immunosuppressive cytotoxic drug . The pathogenesis remain unclear although think autoimmune reaction antigens present cartilage , type II collagen matrilin may evoke symptom . There known clinical laboratory measure predict expression specific disease manifestation overall disease course . Two recently publish case report show association elevate serum IL-6 level relapse polychondritis . In case report , patient refractory relapse polychondritis treat tocilizumab , humanize monoclonal antibody Interleukin 6 receptor , achieve sustained response drug . This single patient trial aim evaluate response Tocilizumab eight year old boy relapse polychondritis show elevated serum IL-6 level respond poorly conventional therapy . The study hypothesis Tocilizumab able control disease patient .</brief_summary>
	<brief_title>Single Patient Study Treat Relapsing Polychondritis With Tocilizumab</brief_title>
	<detailed_description />
	<mesh_term>Polychondritis , Relapsing</mesh_term>
	<criteria>Refractory relapse polychondritis Failed glucocorticoid methotrexate therapy This N=1 clinical trial know patient , therefore , exclusion criterion nonapplicable .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Relapsing Polychondritis</keyword>
	<keyword>Single Patient Study</keyword>
	<keyword>Tocilizumab</keyword>
</DOC>